Center for Drug Evaluation and Research (CDER) Director Janet Woodcock gave a less than enthusiastic reception to an idea of applying breakthrough therapy designation principles to potential generic competitors.
Testifying before the House Energy and Commerce Subcommittee on Health at a March 22 hearing on user fees, Woodcock cautioned of unintended consequences that would likely come with such an approach, including the filing of citizen petitions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?